Mid-Terms Change Pharma’s Prospects to Change Drug Pricing Legislation

With the expected “red wave” failing to materialize and the Democratic party likely maintaining majority rule in the US Senate, the pharma industry is reassessing their prospects in challenging looming drug pricing reform. Pharma companies were basing their ambitions on which party controlled Congress, with many expecting favorable treatment if Republicans gained unilateral control.

According to Ahmed Aboulenein, “Now, with Democrats in control of the Senate and Republicans running the House of Representatives starting in January, the pharmaceutical industry is regrouping for 2023 around a shorter provisions list they say are most problematic as well as turning to other priority areas, sources and experts say.”

To read more, click here.

(Source: Reuters, November 18^th, 2022)